Member Info for Yorkshirepragma

Somebody is...buys 1.9v .9.

and Abcam profits £60m /Ann? V potenial @ Avacta ...
GLA

For sure...& very notably Alistair Smith has mentioned the attention’ drawn to company/ Affimers. Not without good reason !

X 16....work it out ...cheer up..GLA
https://www.equidam.com/ebitda-multiples-trbc-industries/

Lee Thomas Abingdon included in vid. Good listen... all to play for...

https://m.youtube.com/watch?v=T6spa3jd_so&_hsmi=131103890&_hsenc=p2ANqtz-9DhRqYNtgdM7XQagmioZ97n5mYB71Per_ma0NNfY53ibXHbAj1p9CaJA1PfqwfDcgmFRbD8qTh6-SH-qye01hTBJTQKly2zoxILlTqpBscWCg8OUo

Clearly silly to get too excited over a holding,
That aside Avacta has 2 splendid stand out near/ medium term products which are game changing ie Affixers offering more a robust chemistry within LFT/ other testing products, and (potential )anti cancer enhancement therapy.
The latter. Is almost certainly going to market ,as the data on the efficacy of animal testing is unlikely to be far away from the outcome.
The Leeds medic.running the project tellingly describes how pleasing it may be going forward to offer his patients something more positive .
The markets for the above are ‘large & significant ‘, and biotech valuations would apply ...
GLA

Erratum. That’s good.

Goo Wetherby vibrations I hear.....GLA

Good time to launch U.K.home grown technology test....

Good news likely am sure... attend!

For a CEO to declare he’s very excited by commercial prospects GF is quite ‘come and buy me” language , both for shareholders and potential buyout majors.
Watch this space ...
GLA

And made in God’s county too ..GLA

Glad of interest, new CEO seems capable of delivering. Recent Annual Presentation good source.
GLA

https://www.tissueregenix.com/

Tissue damage repaired by TRX tech. is nothing short of a marvel.
A welcoming and large market for this innovative proven product will do well.
Revised leadership team robust too.
GLA

Interview re providing need to provide PCR testing to allow travel " open up", concluding labs would be unable to cope . concluded LFTs are alternative.
gla

There s some debate re 600m being a built in success” price for LFTs.etc
M.Cap GF likely to be
Rev. X 3-5 , or higher if forward potential from cancer advancement success , ongoing Covid products considered .
Stateside interest .. add some more .
DYOR
GLA

I suspect we are feeling the stateside glow here....great co.
GLA

Infinis&b.. yup... I’d say Av on numerous ‘radars’ ... not surprising in view of prospects and tech. Exclusivity GF.
GLA